Maury Blitman, MD
Hematology & Oncology · Spokane Valley, WANPI 1396713095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,288, 7.8 times the $293 reported in 2019.
Across 175 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$352
- Novartis$331
- Merck$260
- Bristol Myers Squibb$260
- Astellas Pharma US Inc$231
- Janssen Scientific Affairs, LLC$228
- plus $3K from 38 others
Across 97 payments — averaging $2891.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$183K
- Astrazeneca UK Limited$37K
- Veru Inc.$25K
- AstraZeneca$25K
- Beigene USA, Inc.$7K
- Merck$4K
- plus $512 from 1 others
What the payments were for
- Food & beverage$4,07593%
- Education$2927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,366 in reported general payments places this provider in the 65th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 48 | $903,921 |
| CalquenceAcalabrutinib Maleate | 62 | $635,452 |
| BrukinsaZanubrutinib | 56 | $534,675 |
| ImbruvicaIbrutinib | 24 | $523,031 |
| Lenalidomide | 33 | $510,403 |
| PomalystPomalidomide | 17 | $434,349 |
| RevlimidLenalidomide | 21 | $353,207 |
| XtandiEnzalutamide | 17 | $254,545 |
| IbrancePalbociclib | 13 | $230,602 |
| TagrissoOsimertinib Mesylate | 11 | $183,886 |
| NubeqaDarolutamide | 13 | $177,033 |
| Abiraterone Acetate | 17 | $38,543 |
| Imatinib Mesylate | 21 | $30,396 |
| OrgovyxRelugolix | 11 | $29,657 |
| EliquisApixaban | 25 | $18,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $220 | $903,92148 claims |
| AstraZenecaCalquence, Tagrisso | $352 | $819,33773 claims |
| Beigene USA, Inc.Brukinsa | $19 | $534,67556 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18 | $523,03124 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $221 | $434,34917 claims |
| Bristol Myers SquibbRevlimid | $260 | $353,20721 claims |
| Astellas Pharma US IncXtandi | $231 | $254,54517 claims |
| PfizerIbrance, Eliquis | $225 | $248,97538 claims |
| BayerNubeqa | $105 | $177,03313 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $228 | $38,54317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Spokane Valley
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
- Celestia HiganoSeattle$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.